Combination eravacycline therapy for ventilator‐associated pneumonia due to carbapenem‐resistant Acinetobacter baumannii in patients with COVID‐19: A case series

Carbapenem-resistant Acinetobacter baumannii (CRAB) pneumonia is associated with poor clinical outcomes and increased mortality. Clinical data regarding the optimal treatment of CRAB is limited, and combination therapy is often preferred. Eravacycline has demonstrated in-vitro activity against A. baumannii and has been considered for the treatment of pulmonary infections caused by CRAB.